BRVE insider filings
Braveheart Bio, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen BRVE transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 14 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 13 legs across 10 filings by 18 insiders — 8,835,275 shares, $159,034,950 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: purchase of 1,920,000 shares @ $18.00 ($34,560,000) by Forbion Growth Opportunities Fund III Cooperatief U.A., filed 2026-08-07.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+3 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Braveheart Bio, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | AH Bio Fund IV, L.P. — 10% owner AH Equity Partners Bio IV, L.L.C. — 10% owner Andreessen Marc L — 10% owner HOROWITZ BENJAMIN A — 10% owner | Conversion (C): 9,132,420 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Chimovits Erez — Director, 10% owner | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP IX LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Conversion (C): 9,132,420 · Purchase (P): 1,666,667 @ $18 · Purchase (P): 273,333 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. — 10% owner | Conversion (C): 7,420,091 · Conversion (C): 32,500,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Forbion Growth Opportunities Fund III Cooperatief U.A. — 10% owner Forbion Growth III Management B.V. — 10% owner Forbion Ventures Fund VII Cooperatief U.A. — 10% owner Forbion Ventures VII Management B.V. — 10% owner | Conversion (C): 9,132,420 @ $0 · Conversion (C): 7,990,867 @ $0 · Purchase (P): 1,920,000 @ $18 · Purchase (P): 1,680,000 @ $18 · Conversion (C): 40,000,000 (derivative) @ $0 · Conversion (C): 35,000,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Lohoff Tim — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Rickey James Paul — Chief Financial Officer | Purchase (P): 27,777 @ $18 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Lubner David Charles — Director | Purchase (P): 55,555 @ $18 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Bos Jasper — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Murdoch Travis — CEO and President, Director | Purchase (P): 83,333 @ $18 · Grant/award (A): 550,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Anderson Michele A. — Chief Development Officer | Purchase (P): 1,111 @ $18 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Malek David I — Director | Purchase (P): 4,166 @ $18 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Viehbacher Christopher — Director | Purchase (P): 83,333 @ $18 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-08-07 | 4 | Chimovits Erez — Director, 10% owner | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Braveheart Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Braveheart Bio, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-297456 (S-1) — latest: Final prospectus (424B4), filed 2026-08-06
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BRVE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →